|
1
|
Caldwell S and Argo C: The natural history
of non-alcoholic fatty liver disease. Dig Dis. 28:162–168.
2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Portillo-Sanchez P, Bril F, Maximos M,
Lomonaco R, Bermacki D, Orsak B, Subbarayan S, Webb A, Hecht J and
Cusi K: High prevalence of nonalcoholic fatty liver disease in
patients with type 2 diabetes mellitus and normal plasma
aminotransferase levels. J Clin Endocrinol Metab. 100:2231–2238.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hazlehurst JM, Woods C, Marjot T, Cobbold
JF and Tomlinson JW: Non-alcoholic fatty liver disease and
diabetes. Metabolism. 65:1096–1108. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shibata M, Kihara Y, Taguchi M, Tashiro M
and Otsuki M: Nonalcoholic fatty liver disease is a risk factor for
type 2 diabetes in middle-aged Japanese men. Diabetes Care.
30:2940–2944. 2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chen Z, Yu R, Xiong Y, Du F and Zhu S: A
vicious circle between insulin resistance and inflammation in
nonalcoholic fatty liver disease. Lipids Health Dis.
16(203)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Veyrat-Durebex C, Poher AL, Caillon A,
Somm E, Vallet P, Charnay Y and Rohner-Jeanrenaud F: Improved
leptin sensitivity as a potential candidate responsible for the
spontaneous food restriction of the Lou/C rat. PLoS One.
8(e73452)2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nishi T, Babazono A, Maeda T, Imatoh T and
Une H: Evaluation of the fatty liver index as a predictor for the
development of diabetes among insurance beneficiaries with
prediabetes. J Diabetes Investig. 6:309–316. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schneider AL, Lazo M, Ndumele CE, Pankow
JS, Coresh J, Clark JM and Selvin E: Liver enzymes, race, gender
and diabetes risk, the atherosclerosis risk in communities (ARIC)
study. Diabet Med. 30:926–933. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Remus Popa A, Fratila O, Rus M, Anca Corb
Aron R, Vesa CM, Pantis C, Diaconu C, Bratu O, Bungau S and Nemeth
S: Risk factors for adiposity in the urban population and influence
on the prevalence of overweight and obesity. Exp Ther Med.
20:129–133. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Vesa CM, Popa L, Popa AR, Rus M, Zaha AA,
Bungau S, Tit DM, Corb Aron RA and Zaha DC: Current data regarding
the relationship between type 2 diabetes mellitus and
cardiovascular risk factors. Diagnostics. 10(314)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhou Y and Rui L: Leptin signalling and
leptin resistance. Front Med. 7:207–222. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ernst MB, Wunderlich CM, Hess S, Paehler
M, Mesaros A, Koralov SB, Kleinridders A, Husch A, Münzberg H,
Hampel B, et al: Enhanced Stat3 activation in POMC neurons provokes
negative feedback inhibition of leptin and insulin signaling in
obesity. J Neurosci. 29:11582–11593. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
American Diabetes Association. 2.
Classification and diagnosis of diabetes: Standards of medical care
in diabetes-2020. Diabetes Care. 43 (Suppl 1):S14–S31.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Abdel-Daim MM, El-Tawil OS, Bungau SG and
Atanasov AG: Applications of antioxidants in metabolic disorders
and degenerative diseases: Mechanistic approach. Oxid Med Cell
Longev. 2019(4179676)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pappachan JM, Babu S, Krishnan B and
Ravindran NC: Non-alcoholic fatty liver disease: A clinical update.
J Clin Transl Hepatol. 5:384–393. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Younossi ZM, Koenig AB, Abdelatif D, Fazel
Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty
liver disease-meta-analytic assessment of prevalence, incidence,
and outcomes. Hepatology. 64:73–84. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Balkau B, Lange C, Vol S, Fumeron F and
Bonnet F: Group Study D.E.S.I.R. Nine-year incident diabetes is
predicted by fatty liver indices: The French D.E.S.I.R study. BMC
Gastroenterol. 10(56)2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bedogni G, Bellentani S, Miglioli L,
Masutti F, Passalacqua M, Castiglione A and Tiribelli C: The fatty
liver index: A simple and accurate predictor of hepatic steatosis
in the general population. BMC Gastroenterol. 6(33)2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cansanção K, Silva Monteiro L, Carvalho
Leite N, Dávalos A, Tavares do Carmo MDG and Arantes Ferreira Peres
W: Advanced liver fibrosis is independently associated with
palmitic acid and insulin levels in patients with non-alcoholic
fatty liver disease. Nutrients. 10(1586)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Denkmayr L, Feldman A, Stechemesser L,
Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U,
Buch S, Hampe J, et al: Lean patients with non-alcoholic fatty
liver disease have a severe histological phenotype similar to obese
patients. J Clin Med. 7(562)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Diaconu C, Salmen T, Gaman MA, Bratu OG,
Mischianu D, Marcu RD, Suceveanu AI, Costache RS and Pantea Stoian
A: SGLT2 inhibition in patients with type 2 diabetes and
cardiovascular diseases: Which are the benefits? Rom J Mil Med.
122:16–21. 2019.
|
